CMS unveils inflation drug pricing changes, with a Part B wrinkle coming soon
A flurry of drug-pricing activity at HHS and CMS shows the agencies looking forward to big changes in what they’ll pay pharmaceutical companies for Medicare drugs. Most of these won’t affect providers and patients directly for some time — except for one shift that will appear as early as April 1 for some practices that dispense Part B drugs.
To read the full article, sign in and subscribe to the DecisionHealth Newsletters.